Status:
COMPLETED
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.
Lead Sponsor:
AstraZeneca
Conditions:
Adverse Events
Pharmacokinetic Variables
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to compare the pharmacokinetics of ABT-335 and rosuvastatin from ABT-143 relative to that from the co-administration of ABT-335 and rosuvastatin.
Eligibility Criteria
Inclusion
- Signed informed consent
- Condition of good health
Exclusion
- Currently enrolled in another study
- Females who are pregnant or breast feeding
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00728780
Start Date
August 1 2008
Last Update
September 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 11101
Evansville, Indiana, United States, 47710